Hematopoietic Cell Patents (Class 424/173.1)
  • Patent number: 11207385
    Abstract: In some aspects, the present disclosure provides compositions and methods for treating disease, e.g., inflammatory disease. Compositions herein comprise one or more polypeptide fragments of proopiomelanocortin or variants thereof. The one of more polypeptide fragments of proopiomelanocortin or variants thereof may be linked by a linker, e.g., a peptide linker, to form a fusion polypeptide.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: December 28, 2021
    Assignee: Aequus Biopharma, Inc.
    Inventors: Ronald Berenson, Christopher H. Clegg
  • Patent number: 11154597
    Abstract: Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate a recombinant polytope that is optimized for proper trafficking and processing. In preferred methods, the polytope is encoded in a viral expression system that is used as a therapeutic agent.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: October 26, 2021
    Assignees: NantCell, Inc., Nant Holdings IP, LLC, NantOmics, LLC
    Inventors: Kayvan Niazi, Andrew Nguyen, Shahrooz Rabizadeh, Patrick Soon-Shiong, Stephen Charles Benz
  • Patent number: 11142582
    Abstract: This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: October 12, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen, Jingshu Xie
  • Patent number: 11141480
    Abstract: Methods are provided herein for determining and administering optimized dosing of therapeutic anti-CD47 agents, in a schedule that provides safe escalation of dose while achieving a therapeutic level in a clinically effective period of time. The methods can comprise the steps of clearance, escalation, and maintenance. In one embodiment the dosing regimen administers an initial (i) sub-therapeutic dose of an anti-CD47 agent or (ii) a cytoreductive therapy to achieve a safe level of circulating tumor cells for subsequent treatment (clearance); escalating the dose of an anti-CD47 agent until a therapeutic dose is reached (escalation); and maintaining the therapeutic dose for a period of time sufficient to reduce tumor cells in the bone marrow of the patient (maintenance). In an alternative dosing regimen, a patient determined to have a safe level of circulating tumor cells at presentation is treated by the steps of escalation and maintenance without initial clearance.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 12, 2021
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Forty Seven, Inc.
    Inventors: Ravindra Majeti, Mark P. Chao, Jie Liu, Jens-Peter Volkmer, Irving L. Weissman
  • Patent number: 11098113
    Abstract: The present invention relates to immunoglobulin single variable domains that bind MIF and more in particular to polypeptides that comprise or essentially consist of one or more such immunoglobulin single variable domains; to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: August 24, 2021
    Assignees: VIB VZW, Vrije Universiteit Brussel
    Inventors: Peter Vanlandschoot, Ines Cabrito, Benoît Stijlemans, Amanda Sparkes, Jo Van Ginderachter, Patrick De Baetselier
  • Patent number: 11091542
    Abstract: The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: August 17, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys, Diane Marshall, Daniel John Lightwood
  • Patent number: 10993998
    Abstract: Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: May 4, 2021
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Timothy A. Chan, Naiyer A. Rizvi, Matthew D. Hellmann
  • Patent number: 10898556
    Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: January 26, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
  • Patent number: 10781255
    Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis or prognosis.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: September 22, 2020
    Assignees: DENDROCYTE BIOTECH PTY LTD, THE UNIVERSITY OF QUEENSLAND, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Therese Ann Seldon, David John Munster, Derek Nigel John Hart, Martina Louise Jones, Trent Phillip Munro, Stephen Michael Mahler, Yu Zhou, James D. Marks
  • Patent number: 10732111
    Abstract: A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 4, 2020
    Assignee: HYCOR Biomedical, LLC
    Inventors: Mark David Van Cleve, Taylor Addison Reid, Linda Marie Trondle, Victoria Hung, Yi Luo, Dennis Edwin Rieger, Evan Phillip McMenamy, Nanditha Raghavan, Morkoah Blay Reliford, Douglas John Canfield, Elaine Grace Taine, Edsel Lawrence Noche Sinson, Scott William Vande Wetering, Teri Taylor, Travis Knox, Fran Zylo Cuaresma Jacalne, James Weston, Jennifer Bao-Guey Chan, Stephanie TuVi Ortega, Rachel Sarah Schell, Ronald Norman Diamond, Steve Michael Gann, Eric Darnell Hall, Tae Ho Hwang, John Lewis Morton, Anatoly Moskalev, Marinela Gombosev Stack, Bruce Alan Sargeant, Michelle Fredrika Forshager, Vanessa Camille Chua, Kylie Wilson
  • Patent number: 10703815
    Abstract: The invention relates to antibodies directed against follicle-stimulating hormone (FSH) and capable of potentiating the bioactivity of gonadotropins.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: July 7, 2020
    Assignee: IGYXOS
    Inventors: Elodie Kara, Jeremye Decourtye, Sophie Casteret, Marie-Christine Maurel
  • Patent number: 10690674
    Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: June 23, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Xi-Tao Wang, Olufemi A. Adelakun, Anne C. Lewin, Alan J. Korman, Mark J. Selby, Changyu Wang, Haichun Huang, Karla A. Henning, Nils Lonberg, Mohan Srinivasan, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Susan Chien-Szu Wong, Huiming Li
  • Patent number: 10689454
    Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137. The antibodies and fragments have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 23, 2020
    Assignee: ALLIGATOR BIOSCIENCE AB
    Inventors: Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
  • Patent number: 10647778
    Abstract: Provided herein are bi-specific chimeric antigen receptors (CARs), such as those specific for CD138 and BCMA. Use of the CARs in immune cells (e.g., T cells), compositions, and methods are also contemplated.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: May 12, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventor: Lung-Ji Chang
  • Patent number: 10624974
    Abstract: The present application provides an anti-OX40 human antibody. In particular, a human antibody specifically binding to OX40 is obtained with yeast display screening, and the affinity of the antibody is improved with affinity maturation. The present application also provides a use of the antibody for the prevention or treatment of tumors.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: April 21, 2020
    Assignee: Dingfu Biotarget Co., Ltd.
    Inventors: Ting Xu, Yan Luan, Xiaoxiao Wang, Jianjian Peng, Shuli Ma, Hui Ma, Xiaolong Pan, Shilong Fu, Shanshan Ning, Yeqiong Fei, Meng Zhao
  • Patent number: 10588298
    Abstract: Non-human animals comprising a human or humanized IL-4 and/or IL-4R? nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous IL-4 gene and/or IL-4R? gene with a human IL-4 gene and/or IL-4R? gene in whole or in part, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized IL-4 gene under control of non-human IL-4 regulatory elements is also provided, including non-human animals that have a replacement of non-human IL-4-encoding sequence with human IL-4-encoding sequence at an endogenous non-human IL-4 locus. Non-human animals comprising a human or humanized IL-4R?, gene under control of non-human IL-4R? regulatory elements is also provided, including non-human animals that have a replacement of non-human IL-4R?-encoding sequence with human or humanized IL-4R?-encoding sequence at an endogenous non-human CIL-4R? locus.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: March 17, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Li-Hsien Wang, Yingzi Xue, Andrew J. Murphy, Sean Stevens
  • Patent number: 10532089
    Abstract: Contemplated cancer treatments comprise recursive analysis of patient-, cancer-, and location-specific neoepitopes from various biopsy sites of a patient after treatment or between successive rounds of immunotherapy and/or chemotherapy to inform further immunotherapy. Recursive analysis preferably includes various neoepitope attributes to so identify treatment relevant neoepitopes.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: January 14, 2020
    Assignees: NANTOMICS, LLC, NANT HOLDINGS IP, LLC
    Inventors: Stephen Charles Benz, Kayvan Niazi, Patrick Soon-Shiong, Andrew Nguyen
  • Patent number: 10494433
    Abstract: Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: December 3, 2019
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, Innate Pharma
    Inventors: Pascale Andre, Mathieu Blery, Cecile Bonnafous, Ashok K. Gupta, Luisa M. Salter-Cid, Michael Darron Robbins
  • Patent number: 10441810
    Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 15, 2019
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder, Frederic A. Bourke, Jr., Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
  • Patent number: 10428136
    Abstract: The present invention relates to chimeric antigen receptors (CARs) specific to ICAM-1 comprising I domain of the ?L subunit of human lymphocyte function-associated antigen 1 (LFA-1). The invention particularly relates to CARs comprising human I domains having different affinities (1 mM to 1 nM Kd) to ICAM-1. CAR T cells comprising human I domain having a low affinity (1 to 200 ?M Kd) to ICAM-1 can avoid targeting healthy tissues with basal ICAM-1 expression while simultaneously exhibiting increased potency and long-term efficacy against tumor tissues with high ICAM-1 expression. The present invention also relates to an adoptive cell therapy method for treating cancer by administering the CAR-T cells comprising human I domain to a subject suffering from cancer, whereby the CAR T cells bind to the cancer cells overexpressing ICAM-1 and kill the cancer cells.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 1, 2019
    Assignee: Cornell University, Center for Technology Licensing (“CTL”)
    Inventor: Moonsoo Jin
  • Patent number: 10407471
    Abstract: The present invention relates to a composition for preventing, improving, or treating aging, wherein the composition comprises a recombinant protein of flagellin, which is the constituent of Vibrio vulnificus flagella, fused with a pathogenic protein antigen, as an active component. According to the present invention, the recombinant protein of the present invention can improve external and internal aging-related malfunctions and enhance immunity. Also, the composition of the present invention can easily perform immunization through mucosal administration.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: September 10, 2019
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Kyung A. Cho, Jae Sung Lim, Joon Haeng Rhee
  • Patent number: 10339274
    Abstract: Contemplated antiviral/cancer treatments comprise analysis of neoepitopes from viral DNA that has integrated into the host genome, and design of immunotherapeutic agents against such neoepitopes.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: July 2, 2019
    Assignee: NANTOMICS, LLC
    Inventors: Andrew Nguyen, Stephen Charles Benz, John Zachary Sanborn
  • Patent number: 10106618
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: October 23, 2018
    Assignee: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Patent number: 10000566
    Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 19, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
  • Patent number: 9725519
    Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains an antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 8, 2017
    Assignees: Kinki University, Link Genomics, Inc.
    Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou
  • Patent number: 9725501
    Abstract: The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a two-stage ultrafiltration/diafiltration approach.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: August 8, 2017
    Inventors: Martin Gonzalez, Woody D. Wood, Fred H. Earp
  • Patent number: 9657102
    Abstract: The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: May 23, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Smith, Nicholas J. Papadopoulos
  • Patent number: 9658226
    Abstract: A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: May 23, 2017
    Assignee: Hycor Biomedical, LLC
    Inventors: Mark David Van Cleve, Elaine Grace Taine, Douglas John Canfield, Stephanie TuVi Ortega, Taylor Addison Reid
  • Patent number: 9658225
    Abstract: A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 23, 2017
    Assignee: Hycor Biomedical, LLC
    Inventors: Mark David Van Cleve, Taylor Addison Reid, Linda Marie Trondle, Victoria Hung, Yi Luo, Dennis Edwin Rieger, Evan Phillip McMenamy, Nanditha Raghavan, Morkoah Blay Reliford, Douglas John Canfield, Elaine Grace Taine, Edsel Lawrence Noche Sinson, Scott William Vande Wetering, Teri Taylor, Travis Knox, Fran Zylo Cuaresma Jacalne, James Weston, Jennifer Bao-Guey Chan, Stephanie TuVi Ortega, Rachel Sarah Schell, Ronald Norman Diamond, Steve Michael Gann, Eric Darnell Hall, Tae Ho Hwang, John Lewis Morton, Anatoly Moskalev, Marinela Gombosev Stack, Bruce Alan Sargeant, Michelle Fredrika Forshager, Vanessa Camille Chua, Kylie Wilson
  • Patent number: 9651550
    Abstract: A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: May 16, 2017
    Assignee: Hycor Biomedical, LLC
    Inventors: Mark David Van Cleve, Elaine Grace Taine, Douglas John Canfield, Stephanie TuVi Ortega, Taylor Addison Reid
  • Patent number: 9457052
    Abstract: A method inducing chimerism and allograft tolerance by co-infusion of stem/progenitor-like cells and donor cells, wherein the donor cells can be bone marrow cells. The method also comprises the conditioning comprising depletion of CD4+ and CD8+ T-cells and administration of low doses of anti-neoplastic drugs. The inventive method comprises an aspect wherein allograft tolerance is induced without systemically suppressing the immune system.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 4, 2016
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Thomas A. Davis, Khairul Anam, Eric A. Elster, Douglas K. Tadaki
  • Patent number: 9273141
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: March 1, 2016
    Assignee: Glaxo Group Limited
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Patent number: 9260520
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 16, 2016
    Assignees: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James McGivney, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Patent number: 9244075
    Abstract: The present invention provides compositions and methods useful for diagnosing, treating, and preventing cancer, particularly ovarian cancer and uterine cancer, based on the discovery that the oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor, is also expressed in various cancers, including ovarian cancer and uterine cancer. Six SAS1R variants have been previously identified, and they are encompassed by the invention. The present invention further provides antibodies useful for targeting SAS1R expressing cells and for killing such cells.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: January 26, 2016
    Assignee: University of Virginia Patent Foundation
    Inventors: John C. Herr, Euseblo S. Pires
  • Publication number: 20150147344
    Abstract: The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 28, 2015
    Inventor: Daniel Olive
  • Publication number: 20150140017
    Abstract: The present invention relates to predictors of a cancer patient's responsiveness to immunotherapy for cancer.
    Type: Application
    Filed: March 8, 2013
    Publication date: May 21, 2015
    Inventors: Madhav Dhodapkar, Kavita Dhodapkar
  • Publication number: 20150132255
    Abstract: The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 14, 2015
    Applicant: Bionor Immuno AS
    Inventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold, Lars Hoie, Anker Lundemose, Vidar Wendel Hansen
  • Publication number: 20150132290
    Abstract: The invention provides methods and compositions for administration of allogeneic lymphocytes as an an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T cells from the infused population may augment the ability of non-regulatory T cells to provide help for endogenous effectors of anti-tumor immunity. Allogeneic T cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature T cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector T cells derive from the host.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 14, 2015
    Inventors: Ephraim Joseph Fuchs, Heather Jills Symons, Lode Swinnen
  • Patent number: 9028826
    Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Dartmouth College
    Inventor: Randolph J. Noelle
  • Publication number: 20150125470
    Abstract: Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
    Type: Application
    Filed: March 29, 2013
    Publication date: May 7, 2015
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yoshiharu Hiruma, Jun Hasegawa
  • Publication number: 20150125447
    Abstract: The present invention relates to pharmaceutical combinations CD33 antibodies and de-methylating agents for use in treating diseases like MDS and cancer, especially AML.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Inventor: Karl-Heinz HEIDER
  • Publication number: 20150118252
    Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.
    Type: Application
    Filed: June 13, 2013
    Publication date: April 30, 2015
    Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch
  • Patent number: 9017682
    Abstract: Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of inflammatory conditions, such as neuroinflammatory conditions such as multiple sclerosis, and for the identification and selection of inflammatory cytokine-secreting T cell or a precursor thereof, based on the expression and/or modulation of melanoma cell adhesion molecule (MCAM) are disclosed.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 28, 2015
    Assignee: Val-Chum, Limited Partnership
    Inventors: Alexandre Prat, Romain Cayrol, Nathalie Arbour
  • Publication number: 20150110813
    Abstract: A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs.
    Type: Application
    Filed: November 13, 2014
    Publication date: April 23, 2015
    Inventors: Hong Jiang, Leonard Chess
  • Publication number: 20150104467
    Abstract: Methods for treating and reducing the progression of neurodegenerative diseases, including, without limitation Alzheimer's disease, are provided. The methods of the invention reduce or deplete neutrophil/myeloid cells in the region of the brain by blocking neutrophil/myeloid cell adhesion and interaction with the vascular endothelium, by blocking infiltration of neutrophil/myeloid cells into the brain, by reducing motility of neutrophil/myeloid cells in the parenchyma, by blocking A?-induced activation and adhesion of neutrophil/myeloid cells, and/or by blocking A?-induced integrin activation, degranulation and/or ROS release in neutrophil/myeloid cells.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventor: Gabriela Constantin
  • Publication number: 20150098939
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 9, 2015
    Applicant: SANOFI
    Inventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Carsten CORVEY, Tarik DABDOUBI, Christian ENGEL, Peter FLORIAN, Ingo FOCKEN, Katja KROLL, Jochen KRUIP, Christian LANGE, Thomas LANGER, Martin LORENZ, Vincent MIKOL, Ercole Rao, Peter WONEROW
  • Publication number: 20150098942
    Abstract: OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation.
    Type: Application
    Filed: February 6, 2012
    Publication date: April 9, 2015
    Applicant: Providence Health & Services - Oregon d/b/a Providence Portland Medical Center
    Inventors: Brendan Curti, Magdalena Kovacsovics-Bankowski, Ed Walker, Josh Walker, Andy Weinberg
  • Publication number: 20150086616
    Abstract: Oral non-steroidal anti inflammatory drugs (NSAIDs) are not an effective treatment of Alzheimer's disease, because the brain dose is too low. Nasal delivery of NSAIDs such as ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen, which inhibit the enzymes cyclooxygenase-1 (cox-1) and cox-2, are used to prevent and/or treat Alzheimer's disease, a low grade brain inflammation. The large amount of nasal NSAIDs (e.g., ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen) that reaches the brain far exceeds that from an oral dose. Low-molecular-weight lipophilic drugs, such as ibuprofen, naproxen, indomethacin, diclofenac, and flurbiprofen, are readily absorbed into the brain by the intranasal route. Alzheimer's starts in the entorhinal cortex, which is closely connected to the olfactory nerves, and spreads anatomically in a defined pattern. Therefore, a nasal NSAID would readily reach the region of the brain where it acts therapeutically.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 26, 2015
    Inventor: Steven Lehrer
  • Publication number: 20150086548
    Abstract: Embodiments of the present invention relate to compositions and methods of treating type 1 or type 2 diabetes mellitus or other conditions relating to metabolic dysfunction that may impact insulin secretion or action by administering an islet neogenesis agent in combination with an agent or agents that selectively inhibits, blocks or destroys the autoimmune destruction of pancreatic cells or agents that optimize function within existing islets in patients with type 1 diabetes, type 2 diabetes and related conditions.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 26, 2015
    Inventor: Claresa S. Levetan
  • Publication number: 20150086574
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Application
    Filed: August 12, 2014
    Publication date: March 26, 2015
    Inventors: Holger Karsunky, Ying-Ping Jiang